Public

Carbidopa / Levodopa Formulation



Version Revision Date: SDS Number: Date of last issue: 2020/10/10 2.14 2021/04/09 50116-00017 Date of first issue: 2015/01/23

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Carbidopa / Levodopa Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : JL Raya Pandaan KM. 48

Pandaan, Jawa Timur - Indonesia

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - :

repeated exposure (Oral)

: Category 1 (Central nervous system)

Long-term (chronic) aquatic

hazard

Category 3

GHS label elements

Hazard pictograms :





Signal word : Danger

Hazard statements : H302 Harmful if swallowed.

H361d Suspected of damaging the unborn child.

H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed. H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.



Carbidopa / Levodopa Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Levodopa	59-92-7	>= 60 -<= 100
Carbidopa	38821-49-7	>= 10 -< 25
Cellulose	9004-34-6	< 10
Starch	9005-25-8	< 10
Magnesium stearate	557-04-0	< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.



Carbidopa / Levodopa Formulation

ORGANON

Version **Revision Date:** SDS Number: Date of last issue: 2020/10/10 2021/04/09 50116-00017 Date of first issue: 2015/01/23 2.14

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and Harmful if swallowed.

Suspected of damaging the unborn child.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Protection of first-aiders

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

delayed

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 2020/10/10 2.14 2021/04/09 50116-00017 Date of first issue: 2015/01/23

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation
Advice on safe handling

Use only with adequate ventilation.

: Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Levodopa	59-92-7	TWA	500 μg/m3 (OEB 2)	Internal
Carbidopa	38821-49-7	TWA	2,000 µg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	NAB	10 mg/m3	ID OEL
		TWA	10 mg/m3	ACGIH
Starch	9005-25-8	NAB	10 mg/m3	ID OEL



Carbidopa / Levodopa Formulation

Version **Revision Date:** SDS Number: Date of last issue: 2020/10/10 2021/04/09 50116-00017 Date of first issue: 2015/01/23 2.14

	enough data	Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals				
		TWA	10 mg/m3	ACGIH		
Magnesium stearate	557-04-0	NAB	10 mg/m3	ID OEL		
	enough data	Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals				
		TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH		
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH		

Engineering measures Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material Chemical-resistant gloves

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide Hygiene measures

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance powder

Colour No data available

Odour odourless

Carbidopa / Levodopa Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available



Carbidopa / Levodopa Formulation

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 2020/10/10 2.14 2021/04/09 50116-00017 Date of first issue: 2015/01/23

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,952 mg/kg

Method: Calculation method

Components:

Levodopa:

Acute oral toxicity : LD50 (Rat): 1,780 mg/kg

LD50 (Mouse): 2,363 mg/kg

Carbidopa:

Acute oral toxicity : LD50 (Rat): 4,810 mg/kg

LD50 (Mouse): 1,750 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg



Carbidopa / Levodopa Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Carbidopa:

Species : Rabbit

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Carbidopa:

Species : Rabbit

Result : Mild eye irritation

Starch:

Species : Rabbit

Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.



Carbidopa / Levodopa Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

Respiratory sensitisation

Not classified based on available information.

Components:

Levodopa:

Species : Guinea pig

Result : Not a skin sensitizer.

Carbidopa:

Remarks : No data available

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Magnesium stearate:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Levodopa:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: mouse lymphoma cells

Result: equivocal

Test Type: Micronucleus test

Test system: Chinese hamster lung cells

Result: positive

Test Type: sister chromatid exchange assay Test system: Chinese hamster lung cells

Result: positive

Carbidopa:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: In vitro mammalian cell gene mutation test



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 2020/10/10 2.14 2021/04/09 50116-00017 Date of first issue: 2015/01/23

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Levodopa:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Carbidopa:

Species : Rat Application Route : Oral



Carbidopa / Levodopa Formulation

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 2020/10/10 2.14 2021/04/09 50116-00017 Date of first issue: 2015/01/23

Exposure time : 96 weeks

135 mg/kg body weight

Result : negative

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Levodopa:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 125 mg/kg body weight Symptoms: Skeletal malformations, Visceral malformations

Result: positive

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Test Type: Development

Species: Mouse Application Route: Oral

Developmental Toxicity: LOAEL: 500 mg/kg body weight

Symptoms: Effects on foetal development

Result: positive

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Carbidopa:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 120 mg/kg body weight Symptoms: Reduced body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop: Test Type: Development



Carbidopa / Levodopa Formulation

♣ ORGANON

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

ment Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 120 mg/kg body weight

Result: No teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 120 mg/kg body weight

Result: No teratogenic effects

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:

Levodopa:

Exposure routes : Oral

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.



Carbidopa / Levodopa Formulation



Version Revision Date: SDS Number: Date of last issue: 2020/10/10 2.14 2021/04/09 50116-00017 Date of first issue: 2015/01/23

Repeated dose toxicity

Components:

Levodopa:

Species : Rat

LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 106 Weeks

Target Organs : Central nervous system

Symptoms : Salivation

Species : Monkey
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 22 Weeks

Target Organs : Central nervous system

Carbidopa:

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 96 Weeks

Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 135 mg/kg
Application Route : Oral
Exposure time : 1 yr

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 5 mg/kg
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 238 d

Symptoms : Diarrhoea, Vomiting, Tremors

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Magnesium stearate:



Carbidopa / Levodopa Formulation

ORGANON

Version **Revision Date:** SDS Number: Date of last issue: 2020/10/10 2021/04/09 50116-00017 Date of first issue: 2015/01/23 2.14

Rat **Species**

NOAEL > 100 mg/kg Application Route Ingestion Exposure time 90 Davs

Remarks Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Levodopa:

Ingestion Symptoms: Nausea, central nervous system effects, Drowsi-

ness

Carbidopa:

Symptoms: involuntary movement Ingestion

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Levodopa:

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 16 mg/l

Exposure time: 48 h

Carbidopa:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 35.3 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Cellulose:

LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Toxicity to fish

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

> Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility



Carbidopa / Levodopa Formulation

♣ ORGANON

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

Toxicity to algae/aquatic

plants

: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Levodopa:

octanol/water

Partition coefficient: n-

J. O

log Pow: -2.39

Magnesium stearate:

Partition coefficient: n-

: $\log Pow: > 4$

octanol/water

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-



Carbidopa / Levodopa Formulation

-‡∙ ORGANON

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials

Type of Hazardous Materials Restricted to Import,

Distribution and Supervision

: Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Public ORGANON

Carbidopa / Levodopa Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

16. OTHER INFORMATION

Further information

Sources of key data used to

compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ID OEL : Indonesia. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average ID OEL / NAB : Long term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their



Carbidopa / Levodopa Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2020/10/10

 2.14
 2021/04/09
 50116-00017
 Date of first issue: 2015/01/23

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN